While all geographic regions are primed for a strong rebound from a lackluster performance in 2013, developing markets will lead the way. Other Asia Pacific (excluding China, Japan and China), especially Taiwan, Korea and Indonesia, will perform exceptionally well. China remains the key market for most industry suppliers, while Japan offers significantly improved prospects because […]

Biotechnology R&D expenditures in Spain declined 3.3% in 2012 to €1,455 million ($1,865 million), following a 4.4% decline in 2011, to account for 11% of total Spanish R&D spending. Biotech R&D spending by government, business and higher education declined 3.7%, 2.7% 3.8% to make up 40%, 36% and 24% of total internal biotech R&D expenditures, […]

Uncertainty surrounding the legal requirements for conducting drug trials in India has slowed trial activity. In 2011, India was responsible for $450 million worth of clinical trials. Earlier this year, India’s Supreme Court stopped 157 clinical trials, requiring they undergo review. Also, the government introduced rules making companies responsible for the injury or death of […]

R&D expenditures by UK businesses declined 2% in 2012 in current prices to £17.1 billion ($27.1 billion). In constant prices, they declined 4%. Total civil R&D expenditures, which excludes defense R&D spending, declined 1% to make up 91% of total UK business R&D spending. Pharmaceutical R&D showed the largest decline, falling 15% in current prices, […]

Turkey’s gross expenditure on R&D increased 17.1% in 2012 to TRY 13,062 million ($7,249 million) at current prices. Current costs accounted for 87% of expenditures, and capital costs made up 13%. The business sector performed 45% of R&D and funded 47%. The manufacturing sector accounted for the largest percentage of R&D expenditures by business at […]